The company is one of the few domestic manufacturers with rich independent vaccine product series, with independent products such as group A and group C meningococcal polysaccharide conjugate vaccine, ACYW 135 meningococcal polysaccharide vaccine, micro-card (Mycobacterium bovis for injection) and agent products such as Hib vaccine and live attenuated hepatitis A vaccine. Among them, micro-card is an exclusive product at home and abroad, the only product recommended by WHO in the immunotherapy program for tuberculosis, and is used as a drug in the Tenth Five-Year Plan.
Feng Naxi, president of Merck East China District, said that it will jointly promote cervical cancer vaccine in China market with zhifei Bio (still under approval); Jiang Rensheng, chairman of zhifei Bio, said that sales cooperation is only the first step, and the two sides will carry out more extensive cooperation in the future. For example, zhifei's AC+HIB vaccine is not available at home and abroad, and it can also go abroad in the future.
Zhifei Biological Marketing System
The "technology+market" two-wheel drive mode established by the company, R&D and market promote each other, and there is a virtuous circle of mutual transformation. Accelerate the process of vaccine products from research and development to market value transformation.
The cold chain system will be completed by self-construction according to national requirements, ensuring the seamless cold chain of vaccines during transportation and storage. Through the refrigerated truck with real-time temperature monitoring system and remote automatic monitoring and alarm, the safe and reliable transportation process of vaccine can be ensured, and the quality and quantity can be guaranteed. After the operation of a stable and mature marketing system, the company's products have been supported in the market and the market share has been greatly improved.
Reference to the above content: Baidu Encyclopedia-zhifei Biology